VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
Nagengast, W Lub-de Hooge, M Oosting, S den Dunnen, W Warnders, F Brouwers, A de Jong, J Price, Patricia M Hollema, H Hospers, G
Nagengast, W
Lub-de Hooge, M
Oosting, S
den Dunnen, W
Warnders, F
Brouwers, A
de Jong, J
Price, Patricia M
Hollema, H
Hospers, G
Citations
Altmetric:
Abstract
Non-invasive imaging of angiogenesis could ease the optimization of antiangiogenesis treatments for cancer. In this study, we evaluated the role of VEGF-PET as a biomarker of dynamic angiogenic changes in tumors following treatment with the kinase inhibitor sunitinib. The effects of sunitinib treatment and withdrawal on the tumor was investigated using the new VEGF-PET tracer (89)Zr-ranibizumab as well as (18)F-FDG PET, and (15)O-water PET in mouse xenograft models of human cancer. The obtained imaging results were compared with tumor growth, VEGF plasma levels and immunohistologic analyzes. In contrast to (18)F-FDG and (15)O-water PET, VEGF-PET demonstrated dynamic changes during sunitinib treatment within the tumor with a strong decline in signal in the tumor center and only minimal reduction in tumor rim, with a pronounced rebound after sunitinib discontinuation. VEGF-PET results corresponded with tumor growth and immunohistochemical vascular- and tumor- markers. Our findings highlight the strengths of VEGF-PET imaging to allow serial analysis of angiogenic changes in different areas within a tumor.
Description
Date
2011
Publisher
Collections
Keywords
Type
Article
Citation
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment 2010, 71 (1):143 Cancer Research